Regulatory decisions made by the Food and Drug Administration (FDA) often serve as important catalysts for pharmaceutical stocks. In the following video, health-care analyst Max Macaluso discusses three upcoming FDA decisions -- on drugs developed by pharma giant Merck (MRK +0.40%), GlaxoSmithKline (GSK +0.66%), and needle-free injection pioneer Antares Pharma (ATRS +0.00%) -- and why investors need to keep a close watch on the outcomes of these decisions.
